ROSNANO BOD approved investments in Bioptix Diagnostics, Inc. in the volume of $825ths, the company informed.
The raised funds Bioptix Diagnostics is going to invest in further development of biosensors.
BOD affirmed the contract price on the auditing and approved the deals with the Vera Charity Fund.
ROSNANO (TIN 7728131587) is a co-investor in the nano-technological projects with considerable economic or social potential. Its participation at the initial stages of the projects mitigate the risks for the private investors as partners.
The Corporation is a participant of the projects aimed to build the nanotechnolgical objects including the business-incubators, early investment funds etc.
The 2011-net profit (IAS) rallied down 74.6% to 1.007bn rub. from 3.97bn rub. prior year; revenues dropped to 1.875bn rub. from 2.143bn rub.
The 9-month 2012 net losses (RAS) dropped 48.5% to 1.091bn rub. from 2.118bn rub. prior year period; revenues being doubled to 4.781bn rub. from 1.741bn rub